California Life Sciences (CLS)’s Post

Calling all biotech start-ups and founders: get insider info on the evaluation criteria of big pharma at the next Bayer’s Expert Monday – How does Big Pharma Evaluate Partnering Offers, on June 24 at 11 a.m. EDT/5 p.m. CEST For example, what do they look at when reviewing your pitch deck or partnering offer? Learn what’s considered a solid non-confidential deck that attracts the attention of investors and partners, such as what kind of content matters and practical tips for pitching. Join this live session and growing community of start-ups here 👇 https://lnkd.in/eQ56i3h6 #BayerExpertMondays #collaboratetocure #innovation #startups #partnerships #biotechnology #collaboration #teambayer

Multiomics diagnostic startup Pleno Inc. has raised $25M in a series B funding round led by Deerfield Management, Foresite Capital, and Medical Excellence Capital, LLC. The funds will support the commercial launch of Pleno's Hypercoding technology, aimed at revolutionizing multiomics analysis for clinical applications. Conor Hale | Fierce Biotech https://lnkd.in/g_CiTsCF #HealthTech

Pathway to Cures (P2C) was thrilled to participate in & sponsor SmartHealth Catalyzer, Inc. Best of the BioMidwest event at Portal Innovations, LLC Portal Pours event in Chicago on Wednesday, June 12th. Other sponsors included: Prendio Inotiv BioProcure, Inc. TMX Group The event featured the Top 10 Most Promising New Therapeutics and MedTech discovered at Midwest universities and research hospitals. Each company had an opportunity to pitch a request for financial support to further their research & development. Companies showcased at the event included: Andrew Cothrel, Kilele Health Brian Cunningham, Atzeyo Biosensors, Inc. Dennis Hallahan, WashU Radiation Oncology Doug Miller, Impower Health Inc Doris Benbrook, OK Safe Remedies Jed White, Tundra Targeted Therapeutics Jill Kolesar, VesiCure Technologies Paul Trippier, University of Nebraska Medical Center Steven Burns, Lighthanded Enterprises William Donaldson, Estrigenix Therapeutics, Inc. Each speaker had 4 minutes to "pitch" and share compelling reasons why they would be the best emerging biotech company venture fund investors to consider. Each attendee had 1,000 SmartHealth Catalyzer, Inc. dollars to "invest" and the biotech with the most funds raised received bragging rights. Congratulations to the winning pitch by Jill Kolesar & VesiCure Technologies who are "Harnessing the immune system to cure cancer" by focusing on Pancreas, Ovarian, & Prostate cancers. This event showcased incredibly talented researchers working on new technologies, therapies, devices, and cures to improve our global health. We encourage you to investigate what these folks are up to and consider an investment in one or more of these emerging biotechs. #biotechnology #venture #ventureinvesting #research (Below - pictured left to right: Tim Brent, Venture Principal, P2C Renee Peck, Sr. Development Director, P2C Tom Denison, CEO, SmartHealth Catalyzer Sharon A. Richardson PhD, Board Member, P2C)

General Proximity, a San Francisco, CA-based biotech platform company, raised $16M in funding. The round was led by Aydin Senkut at Felicis. Other investors included Y Combinator, age1, Modi Ventures, Wilson Sonsini, as well as several angel investors including Jeff Dean (Head of Google AI), Uri Lopatin (Khosla, YC, Pardes), Ben Mann (Co-Author GPT-3, Co-Founder Anthropic), Alec Nielsen (CEO Asimov), Trevor Martin (CEO Mammoth), Juan Benet (Founder Filecoin), Nish Bhat (Co-Founder Color Health), Jim Dahl(Rock Creek Capital), and De Thompson V (Legends Capital). The company intends to use the funds to accelerate the development of treatments targeting proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity. https://lnkd.in/gkM3BB8g

Hong Kong based ORI Capital recently final closed their second fund, ORI Fund II. 💸 $260 Million total commitments for Second Life Sciences Fund 💡 Growth-oriented venture investments into early-stage #biotech companies in the areas of #diagnostics, #drugdelivery, and #therapeutics focused on the disease areas with the highest mortality rates: cancer, cardiovascular and neurodegenerative diseases. 🌍 Globally 📈 Notable exits include: CG Oncology’s, Orchard Therapeutics - U.S. and TriSalus Life Sciences Nasdaq listings; and Semma Therapeutics which was acquired by Vertex in 2019 for $950 million in cash. Current portfolio companies include Pillar Biosciences Incorporated, AffyImmune Therapeutics and Enable Injections, Inc.. 💭 “We are in a golden-era of innovation across the intersection of #AI and biology, where technological breakthroughs are creating new approaches to diagnosing and treating disease” - Simone Song, Founding Partner, ORI Capital 🗞️By Business Wire https://lnkd.in/dZRgED2U 👏 For the #AudaciousInvestors unleashing innovation and empowering tomorrow🚀 Simone Song I Dicky To I Gang Song I Elaine Yang I Arnold Ching, I Danny Wong I Anthony S. I Nico Zheng I Sarah Oi Kwan Mak I Otto Cheung I Edward Tung I Team Ori … #venturecapital #vc #funds #startups #entrepreneurs #funding #tech #ai #entrepreneurship #technology #innovation #bigdata #hongkong #asia

🚀ARCH Venture Partners has just announced it closed its $3B Fund XIII, positioning itself as a key player in driving the next wave of biotech innovation. 🌱 This fund will fuel early-stage biotechs focusing on AI-driven drug discovery, cell and gene therapies, oncology, rare diseases, and immunology. But ARCH isn’t the only fund making headlines this year. Here’s how others are shaping up: 💡 Other Notable Funds Raised in 2024: ➡️ Flagship Pioneering raised a $3.4B fund, targeting early-stage biotech companies with a strong emphasis on therapeutics and diagnostics innovations. ➡️ Scion Life Sciences launched a fund over $300M, aiming to build a select number of durable startups with ample funding and resources, similar to the strategies used by Flagship and ARCH. They focus on biopharma, medtech, and diagnostics, and aim to scale this fund toward $1B. ➡️ Sands Capital closed its $560M third life sciences fund. As a crossover fund, it invests in clinical-stage companies developing therapeutics, diagnostics, and digital health solutions. ➡️ J.P. Morgan’s Private Financing Arm introduced a $500M biotech fund, targeting early to growth-stage biotechs with a focus on therapeutics, platform technologies, and health tech. ➡️ Foresite Capital completed a $900M sixth fund, backing companies like Xaira and Alumis, with an emphasis on AI-driven drug discovery, immunology, and precision medicine. These substantial fundraises reflect increased confidence in biotech's potential to revolutionize healthcare through AI, precision medicine, and advanced therapies. 🔬 🧠🌩️ What trends do you think will define biotech investments in the coming years? #BiotechInvesting #VentureCapital #BiotechFunding #AI #PrecisionMedicine

🌟 Digital Therapeutics (DTx) Global Startups Highlights Part 2 🌍 💡 Featuring 15 DTx startups shaping the future of healthcare through innovation ➡️ BioBeats: Harnessing AI and biometric data to combat stress and anxiety, now part of Huma's predictive care portfolio. Fantàsha Kassam Sofia Hmich ➡️ Blue Note Therapeutics: Supporting cancer patients' mental health with prescription digital therapeutics. Diane M. Simard Marcus Neubauer, MD Amb. Grace B. Charrier ➡️ Bold Health: Empowering GI disorder management with tech-enabled, patient-centered care. Elena Mustatea ➡️ Brain+ A/S: Pioneering non-pharmacological dementia therapies for improved cognitive health. Kim Baden-Kristensen Simon Nielsen Nahid Zokaei ➡️ Braingaze: Leveraging eye-tracking technology for precise ADHD and autism diagnoses. Laszlo Bax Hans Supèr ➡️ Cappa Health: Transforming chronic disease care with engaging, scalable digital programs. Ray Lyons Richard Lee ➡️ Cara Care: Innovating GI health management through comprehensive digital tools for IBS, IBD, and more. James Mapes Josep Ll. Sanfeliu Felix Köhler ➡️ Ciba Health: Addressing root causes of chronic diseases with functional medicine principles. Innocent C. Markyia Nichols, M.D. Jimmy Lee Anand Narayan Julien L. Pham, MD, MPH ➡️ Cognes Medical Solutions: Democratizing dementia care through accessible, early-detection tools. Sandra Challma ➡️ CogniFit: Enhancing cognitive health worldwide with brain training and assessments. Carlos Rodriguez Marcos Val ➡️ CognoTrain: Supporting Alzheimer's patients with personalized cognitive training and wearables. Sahar Jahanikia Michael Gaenzler ➡️ Crest Digital Therapeutics: Transforming psychiatric care for chronic disorders like bipolar disorder. John B. Stephen Hamm, MBA ➡️ CyberLiver: Tackling liver disease management with data-driven, non-invasive digital solutions. Ravi Kumar Alex Prabu Palanisamy ➡️ dThx – Digital Therapeutics AG – Digital Therapeutics: Advancing chronic disease care with evidence-based, personalized interventions. Thomas Guggi Kelley MBA ➡️ DynamiCare Health: Empowering addiction recovery through scalable digital therapeutic platforms. Bowker, MBA David R. Gastfriend, M.D. Eric Gastfriend ➡️ Elona Health: Revolutionizing psychotherapy with innovative, patient-focused digital tools. Magnus Schückes Leon Hillebrandt   📘 Global Digital Therapeutics (DTx) Startups Yellow Book by Alex G. Lee, PhD, JD Your ultimate guide to 207 leading DTx startups from 28 countries 🌏 – perfect for healthcare leaders, tech enthusiasts, and investors! Video Link: https://lnkd.in/eQsGWmhv #DigitalTherapeutics #Healthcare #DigitalHealth #DTx

The biopharma industry is always in need of talented minds to take promising pipelines to the clinic and beyond. A good biotech entrepreneur is able to cope with change and failure and has proven their expertise in hitting milestones, be it in the lab or when raising funds to bring their technologies and therapies to market. We reached out to venture capitalists to nominate prominent founders and entrepreneurs in the biotech industry who are committed to bringing potentially life-changing treatments to market and have come a long way in doing so. Here are their top picks

General Proximity, a San Francisco, CA-based biotech platform company, raised $16M in funding. The round was led by Aydin Senkut at Felicis. Other investors included Y Combinator, age1, Modi Ventures, Wilson Sonsini, as well as several angel investors including Jeff Dean (Head of Google AI), Uri Lopatin (Khosla, YC, Pardes), Ben Mann (Co-Author GPT-3, Co-Founder Anthropic), Alec Nielsen (CEO Asimov), Trevor Martin (CEO Mammoth), Juan Benet (Founder Filecoin), Nish Bhat (Co-Founder Color Health), Jim Dahl(Rock Creek Capital), and De Thompson V (Legends Capital). The company intends to use the funds to accelerate the development of treatments targeting proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity. https://lnkd.in/gkM3BB8g

New Post: Biotech platform General Proximity lands $16m seed - General Proximity, a San Francisco-based biotech platform founded in 2019, has raised $16 million in seed funding led by Aydin Senkut of Felicis, with additional support from Y Combinator, age1, Modi Ventures, and Wilson Sonsini. The funding will expedite the development of treatments targeting undruggable proteins linked to cancer, cardiometabolic diseases, neurodegeneration, and longevity. Senkut expressed confidence in General Proximity's innovative approach to drug discovery, emphasizing its potential to address significant health challenges and enhance human healthspan. Felicis manages over $3 billion in capital, focusing on early-stage investments. Read the full article here https://lnkd.in/dqSAWbEp #Venturecapital #VC #investment #LP #Limited Partner